Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ZAI LAB LIMITED

(ZLAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zai Lab : Says First Patient Treated in China Portion of Global Study of Odronextamab for B-Cell Non-Hodgkin Lymphoma Treatment

10/25/2021 | 11:12am EST


ę MT Newswires 2021
All news about ZAI LAB LIMITED
04:19pCitigroup Raises Price Target for Zai Lab to $231 From $217, Maintains Buy Rating
MT
07:58aZai Lab Says New Indication for Its Ovarian Cancer Drug Added to China's National Reimb..
MT
07:52aZAI LAB : Announces Inclusion of ZEJULA« (Niraparib) in China's National Reimbursement Dru..
PU
07:47aZAI LAB LTD : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07:30aZai Lab Announces Inclusion of ZEJULA« (Niraparib) in China's National Reimbursement Dr..
AQ
11/30Zai Lab's Late-Stage Ovarian Cancer Trial Meets Primary Endpoint
MT
11/30Zai Lab Study for Ovarian Cancer Treatment Meets Primary Endpoint
DJ
11/30Zai Lab Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA« (Nirapar..
GL
11/30Zai Lab Limited Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA?
CI
11/26Asian ADRs Tumble in Friday Trading
MT
More news
Analyst Recommendations on ZAI LAB LIMITED
More recommendations
Financials (USD)
Sales 2021 152 M - -
Net income 2021 -609 M - -
Net cash 2021 1 397 M - -
P/E ratio 2021 -9,85x
Yield 2021 -
Capitalization 6 302 M 6 302 M -
EV / Sales 2021 32,3x
EV / Sales 2022 17,4x
Nbr of Employees 1 194
Free-Float 99,9%
Chart ZAI LAB LIMITED
Duration : Period :
Zai Lab Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZAI LAB LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 65,37 $
Average target price 195,41 $
Spread / Average Target 199%
EPS Revisions
Managers and Directors
Ying Du Chairman & Chief Executive Officer
Tao Fu President, Chief Operating Officer & Director
Billy Cho Chief Financial Officer
Ning Xu Executive VP & Head-Clinical Operations
James Yan Chief Operating Officer-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ZAI LAB LIMITED-47.21%6 887
CSL LIMITED5.12%98 819
WUXI BIOLOGICS (CAYMAN) INC.0.39%55 833
SAMSUNG BIOLOGICS CO.,LTD.8.96%50 185
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-6.27%33 568